¹Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland
²College of Social Work, The Ohio State University, Columbus
³Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland

Read article on JAMA Network

Read Article Take Quiz

Key Points

Question Is psilocybin-assisted therapy efficacious among patients with major depressive disorder?

Findings In this randomized clinical trial of 24 participants with major depressive disorder, participants who received immediate psilocybin-assisted therapy compared with delayed treatment showed improvement in blinded clinician rater–assessed depression severity and in self-reported secondary outcomes through the 1-month follow-up.

Meaning This randomized clinical trial found that psilocybin-assisted therapy was efficacious in producing large, rapid, and sustained antidepressant effects in patients with major depressive disorder.

Abstract

Importance Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression.

Objective To investigate the effect of psilocybin therapy in patients with MDD.

Design, Setting, and Participants This randomized, waiting list–controlled clinical trial was conducted at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore, Maryland. Adults aged 21 to 75 years with an MDD diagnosis, not currently using antidepressant medications, and without histories of psychotic disorder, serious suicide attempt, or hospitalization were eligible to participate. Enrollment occurred between August 2017 and April 2019, and the 4-week primary outcome assessments were completed in July 2019. A total of 27 participants were randomized to an immediate treatment condition group (n = 15) or delayed treatment condition group (waiting list control condition; n = 12). Data analysis was conducted from July 1, 2019, to July 31, 2020, and included participants who completed the intervention (evaluable population).

Interventions Two psilocybin sessions (session 1: 20 mg/70 kg; session 2: 30 mg/70 kg) were given (administered in opaque gelatin capsules with approximately 100 mL of water) in the context of supportive psychotherapy (approximately 11 hours). Participants were randomized to begin treatment immediately or after an 8-week delay.

Main Outcomes and Measures The primary outcome, depression severity was assessed with the GRID-Hamilton Depression Rating Scale (GRID-HAMD) scores at baseline (score of ≥17 required for enrollment) and weeks 5 and 8 after enrollment for the delayed treatment group, which corresponded to weeks 1 and 4 after the intervention for the immediate treatment group. Secondary outcomes included the Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR).

Results Of the randomized participants, 24 of 27 (89%) completed the intervention and the week 1 and week 4 postsession assessments. This population had a mean (SD) age of 39.8 (12.2) years, was composed of 16 women (67%), and had a mean (SD) baseline GRID-HAMD score of 22.8 (3.9). The mean (SD) GRID-HAMD scores at weeks 1 and 4 (8.0 [7.1] and 8.5 [5.7]) in the immediate treatment group were statistically significantly lower than the scores at the comparable time points of weeks 5 and 8 (23.8 [5.4] and 23.5 [6.0]) in the delayed treatment group. The effect sizes were large at week 5 (Cohen d = 2.5; 95% CI, 1.4-3.5; P < .001) and week 8 (Cohen d = 2.6; 95% CI, 1.5-3.7; P < .001). The QIDS-SR documented a rapid decrease in mean (SD) depression score from baseline to day 1 after session 1 (16.7 [3.5] vs 6.3 [4.4]; Cohen d = 2.6; 95% CI, 1.8-3.5; P < .001), which remained statistically significantly reduced through the week 4 follow-up (6.0 [5.7]; Cohen d = 2.3; 95% CI, 1.5-3.0; P < .001). In the overall sample, 17 participants (71%) at week 1 and 17 (71%) at week 4 had a clinically significant response to the intervention (≥50% reduction in GRID-HAMD score), and 14 participants (58%) at week 1 and 13 participants (54%) at week 4 were in remission (≤7 GRID-HAMD score).

Conclusions and Relevance Findings suggest that psilocybin with therapy is efficacious in treating MDD, thus extending the results of previous studies of this intervention in patients with cancer and depression and of a nonrandomized study in patients with treatment-resistant depression.

Trial Registration ClinicalTrials.gov Identifier: NCT03181529

Take Quiz

Buy This Activity

Article Information

Accepted for Publication: July 31, 2020.

Published Online: November 4, 2020. doi:10.1001/jamapsychiatry.2020.3285

Correction: This article was corrected on February 10, 2021, to fix errors in the Abstract Results and Results section.

Corresponding Authors: Alan K. Davis, PhD (davis.5996@osu.edu), and Roland R. Griffiths, PhD (rgriff@jhmi.edu), Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224.

Author Contributions: Drs Davis and Griffiths had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Davis, Barrett, May, Cosimano, Johnson, Griffiths.

Acquisition, analysis, or interpretation of data: Davis, Barrett, May, Sepeda, Johnson, Finan, Griffiths.

Drafting of the manuscript: Davis, Barrett, May, Cosimano, Sepeda, Griffiths.

Critical revision of the manuscript for important intellectual content: Davis, Barrett, May, Sepeda, Johnson, Finan, Griffiths.

Statistical analysis: Davis, Griffiths.

Obtained funding: Barrett, Griffiths.

Administrative, technical, or material support: Davis, Barrett, May, Cosimano, Sepeda, Finan, Griffiths.

Supervision: Davis, Barrett, May, Cosimano, Johnson, Griffiths.

Conflict of Interest Disclosures: Dr Davis reported being a board member at Source Research Foundation. Dr Johnson reported receiving grants from Heffter Research Institute outside the submitted work and personal fees as a consultant and/or advisory board member from Beckley Psychedelics Ltd, Entheogen Biomedical Corp, Field Trip Psychedelics Inc, Mind Medicine Inc, and Otsuka Pharmaceutical Development & Commercialization Inc. Dr Griffiths reported being a board member at Heffter Research Institute and receiving grants from Heffter Research Institute outside the submitted work. No other disclosures were reported.

Funding/Support: This study was funded in part by a crowd-sourced funding campaign organized by Tim Ferriss; a grant from the Riverstyx Foundation; and grants from Tim Ferriss, Matt Mullenweg, Craig Nerenberg, Blake Mycoskie, and the Steven and Alexandra Cohen Foundation. Drs Davis and May were supported by postdoctoral training grant T32DA07209 from NIDA. Dr Finan was supported by grant K23DA035915 from NIDA. Drs Griffiths and Johnson were partially supported by grant R01DA03889 from NIDA. The Center for Psychedelic and Consciousness Research is funded by the Steven and Alexandra Cohen Foundation and has received support from Tim Ferriss, Matt Mullenweg, Craig Nerenberg, and Blake Mycoskie.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Annie Umbricht, MD, and Eric Strain, MD, provided medical oversight during the study sessions. Jessiy Salwen, PhD, and Mary Bailes, LCPC, served as blinded clinician raters. Natalie Gukasyan, MD; Laura Doyle, BA; John Clifton, BS; Kasey Cox, MS; and Rhiannon Mayhugh, PhD, facilitated the intervention sessions. These individuals, from Johns Hopkins University, received no additional compensation, outside of their usual salary, for their contributions.

References

World Health Organization. Depression fact sheet. World Health Organization. Published December 2019. Accessed January 11, 2020. https://www.who.int/mediacentre/factsheets/fs369/en/

Walker ER , McGee RE , Druss BG . Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334-341. doi:10.1001/jamapsychiatry.2014.2502 PubMed Google Scholar Crossref

Hasin DS , Sarvet AL , Meyers JL , et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75(4):336-346. doi:10.1001/jamapsychiatry.2017.4602 PubMed Google Scholar Crossref

Greenberg PE , Fournier A-A , Sisitsky T , Pike CT , Kessler RC . The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155-162. doi:10.4088/JCP.14m09298 PubMed Google Scholar Crossref

Kolovos S , van Tulder MW , Cuijpers P , et al. The effect of treatment as usual on major depressive disorder: a meta-analysis. J Affect Disord. 2017;210:72-81. doi:10.1016/j.jad.2016.12.013 PubMed Google Scholar Crossref

Morilak DA , Frazer A . Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol. 2004;7(2):193-218. doi:10.1017/S1461145704004080 PubMed Google Scholar Crossref

Gaynes BN , Warden D , Trivedi MH , Wisniewski SR , Fava M , Rush AJ . What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439-1445. doi:10.1176/ps.2009.60.11.1439 PubMed Google Scholar Crossref

Nemeroff CB . Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(suppl 8):17-25.PubMed Google Scholar Crossref

Abdallah CG , Sanacora G , Duman RS , Krystal JH . The neurobiology of depression, ketamine and rapid-acting antidepressants: is it glutamate inhibition or activation? Pharmacol Ther. 2018;190:148-158. doi:10.1016/j.pharmthera.2018.05.010 PubMed Google Scholar Crossref

10.

Dutta A , McKie S , Deakin JFW . Ketamine and other potential glutamate antidepressants. Psychiatry Res. 2015;225(1-2):1-13. doi:10.1016/j.psychres.2014.10.028 PubMed Google Scholar Crossref

11.

Fond G , Loundou A , Rabu C , et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl). 2014;231(18):3663-3676. doi:10.1007/s00213-014-3664-5 PubMed Google Scholar Crossref

12.

Morgan CJA , Curran HV ; Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction. 2012;107(1):27-38. doi:10.1111/j.1360-0443.2011.03576.x PubMed Google Scholar Crossref

13.

Martín-Ruiz R , Puig MV , Celada P , et al. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci. 2001;21(24):9856-9866. doi:10.1523/JNEUROSCI.21-24-09856.2001 PubMed Google Scholar Crossref

14.

Vollenweider FX , Kometer M . The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11(9):642-651. doi:10.1038/nrn2884 PubMed Google Scholar Crossref

15.

Nichols DE . Psychedelics. Pharmacol Rev. 2016;68(2):264-355. doi:10.1124/pr.115.011478 PubMed Google Scholar Crossref

16.

Griffiths RR , Johnson MW , Carducci MA , et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197. doi:10.1177/0269881116675513 PubMed Google Scholar Crossref

17.

Ross S , Bossis A , Guss J , et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165-1180. doi:10.1177/0269881116675512 PubMed Google Scholar Crossref

18.

Carhart-Harris RL , Bolstridge M , Rucker J , et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627. doi:10.1016/S2215-0366(16)30065-7 PubMed Google Scholar Crossref

19.

Goldberg SB , Pace BT , Nicholas CR , Raison CL , Hutson PR . The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Res. 2020;284:112749. doi:10.1016/j.psychres.2020.112749 PubMed Google Scholar

20.

Gable RS . Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. Am J Drug Alcohol Abuse. 1993;19(3):263-281. doi:10.3109/00952999309001618 PubMed Google Scholar Crossref

21.

Gable RS . Acute toxic effects of club drugs. J Psychoactive Drugs. 2004;36(3):303-313. doi:10.1080/02791072.2004.10400031 PubMed Google Scholar Crossref

22.

Johnson MW , Griffiths RR , Hendricks PS , Henningfield JE . The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018;142:143-166. doi:10.1016/j.neuropharm.2018.05.012 PubMed Google Scholar Crossref

23.

Studerus E , Kometer M , Hasler F , Vollenweider FX . Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434-1452. doi:10.1177/0269881110382466 PubMed Google Scholar Crossref

24.

First MB , Williams JBW , Karg RS , Spitzer RL . Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV). American Psychiatric Association; 2016.

25.

Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.1136/jnnp.23.1.56 PubMed Google Scholar Crossref

26.

Williams JBW , Kobak KA , Bech P , et al. The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol. 2008;23(3):120-129. doi:10.1097/YIC.0b013e3282f948f5 PubMed Google Scholar Crossref

27.

Wei LJ , Lachin JM . Properties of the urn randomization in clinical trials. Control Clin Trials. 1988;9(4):345-364. doi:10.1016/0197-2456(88)90048-7 PubMed Google Scholar Crossref

28.

Fekadu A , Wooderson S , Donaldson C , et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry. 2009;70(2):177-184. doi:10.4088/JCP.08m04309 PubMed Google Scholar Crossref

29.

Carey V , Gentleman R . randPack: Randomization routines for clinical trials. R package version 1.32.0. Bioconductor; 2018. Accessed August 1, 2017. https://www.bioconductor.org/packages/release/bioc/html/randPack.html

30.

R Foundation. R Project for Statistical Computing. Accessed August 1, 2017. https://www.R-project.org/

31.

Johnson M , Richards W , Griffiths R . Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603-620. doi:10.1177/0269881108093587 PubMed Google Scholar Crossref

32.

Griffiths RR , Richards WA , McCann U , Jesse R . Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187(3):268-283. doi:10.1007/s00213-006-0457-5 PubMed Google Scholar Crossref

33.

Griffiths RR , Johnson MW , Richards WA , Richards BD , McCann U , Jesse R . Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011;218(4):649-665. doi:10.1007/s00213-011-2358-5 PubMed Google Scholar Crossref

34.

First MB , Williams JBW , Benjamin LS , Spitzer RL . Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ). American Psychiatric Association; 2016.

35.

First MB , Williams JBW , Benjamin LS , Spitzer RL . User’s Guide for the Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD). American Psychiatric Association; 2016.

36.

Morey LC . Personality assessment inventory (PAI). In: Cautin RL , Lilienfeld SO , eds. The Encyclopedia of Clinical Psychology. John Wiley & Sons, Inc; 2015:1-10. doi:10.1002/9781118625392.wbecp284

37.

International Society for CNS Drug Development. GRID-HAMD-17 Structured Interview Guide. ISCDD; 2003.

38.

Zimmerman M , Martinez JH , Young D , Chelminski I , Dalrymple K . Severity classification on the Hamilton depression rating scale. J Affect Disord. 2013;150(2):384-388. doi:10.1016/j.jad.2013.04.028 PubMed Google Scholar Crossref

39.

Rush AJ , Trivedi MH , Ibrahim HM , et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. doi:10.1016/S0006-3223(02)01866-8 PubMed Google Scholar Crossref

40.

Beck AT , Steer RA , Ball R , Ranieri W . Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess. 1996;67(3):588-597. doi:10.1207/s15327752jpa6703_13 PubMed Google Scholar Crossref

41.

Kroenke K , Spitzer RL . The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32(9):509-515. doi:10.3928/0048-5713-20020901-06 Google Scholar Crossref

42.

Posner K , Brent D , Lucas C , et al. Columbia-Suicide Severity Rating Scale (C-SSRS). Columbia University Medical Center; 2008.

43.

Posner K , Brown GK , Stanley B , et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277. doi:10.1176/appi.ajp.2011.10111704 PubMed Google Scholar Crossref

44.

Hamilton M . The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55. doi:10.1111/j.2044-8341.1959.tb00467.x PubMed Google Scholar Crossref

45.

Spielberger CD , Gorsuch RL , Lushene R , Vagg PR , Jacobs GA . Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press; 1983.

46.

Corp IBM . IBM SPSS Statistics for Windows. Version 25. IBM Corp; 2018.

47.

Grob CS , Danforth AL , Chopra GS , et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71-78. doi:10.1001/archgenpsychiatry.2010.116 PubMed Google Scholar Crossref

48.

Johnson MW , Garcia-Romeu A , Griffiths RR . Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43(1):55-60. doi:10.3109/00952990.2016.1170135 PubMed Google Scholar Crossref

49.

Bogenschutz MP , Forcehimes AA , Pommy JA , Wilcox CE , Barbosa PC , Strassman RJ . Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289-299. doi:10.1177/0269881114565144 PubMed Google Scholar Crossref

50.

Garcia-Romeu A , Griffiths RR , Johnson MW . Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7(3):157-164. doi:10.2174/1874473708666150107121331 PubMed Google Scholar Crossref

51.

Roseman L , Nutt DJ , Carhart-Harris RL . Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2018;8:974. doi:10.3389/fphar.2017.00974 PubMed Google Scholar Crossref

52.

Griffiths RR , Johnson MW , Richards WA , et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018;32(1):49-69. doi:10.1177/0269881117731279 PubMed Google Scholar Crossref

53.

Davis AK , Barrett FS , Griffiths RR . Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci. 2020;15:39-45. doi:10.1016/j.jcbs.2019.11.004 PubMed Google Scholar Crossref

54.

Garcia-Romeu A , Davis AK , Erowid F , Erowid E , Griffiths RR , Johnson MW . Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol. 2019;33(9):1088-1101. doi:10.1177/0269881119845793 PubMed Google Scholar Crossref

55.

Garcia-Romeu A , Davis AK , Erowid E , Erowid F , Griffiths RR , Johnson MW . Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. Front Psychiatry. 2020;10:955. doi:10.3389/fpsyt.2019.00955 PubMed Google Scholar Crossref

56.

Barrett FS , Doss MK , Sepeda ND , Pekar JJ , Griffiths RR . Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10(1):2214. doi:10.1038/s41598-020-59282-y PubMed Google Scholar Crossref

57.

Rubin A , Yu M . Within-group effect size benchmarks for cognitive–behavioral therapy in the treatment of adult depression. Soc Work Res. 2017;41(3):135-144. doi:10.1093/swr/svx011 Google Scholar Crossref

58.

Fournier JC , DeRubeis RJ , Hollon SD , et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53. doi:10.1001/jama.2009.1943 PubMed Google Scholar Crossref

59.

de Maat SM , Dekker J , Schoevers RA , de Jonghe F . Relative efficacy of psychotherapy and combined therapy in the treatment of depression: a meta-analysis. Eur Psychiatry. 2007;22(1):1-8. doi:10.1016/j.eurpsy.2006.10.008 PubMed Google Scholar Crossref

60.

Cuijpers P , van Straten A , Warmerdam L , Andersson G . Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depress Anxiety. 2009;26(3):279-288. doi:10.1002/da.20519 PubMed Google Scholar Crossref

61.

Cuijpers P , Sijbrandij M , Koole SL , Andersson G , Beekman AT , Reynolds CF III . Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13(1):56-67. doi:10.1002/wps.20089 PubMed Google Scholar Crossref

62.

US Food and Drug Administration. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Demonstrating substantial evidence of effectiveness for human drug and biological products. Draft guidance for industry. Published June 1, 2020. Accessed Month date, year. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products

Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderA Randomized Clinical Trial

Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression—Quo Vadis?

Errors in Response Rate, Effect Sizes, and Confidence Intervals

Errors in a Response Rate and in Effect Sizes in Study of Psilocybin-Assisted Therapy for Major Depressive Disorder